☆ 4.6 Meeting Abstract

PHARMACODYNAMIC RELATIONSHIP BETWEEN PCSK9, ALIROCUMAB, AND LDL-C LOWERING IN FOUR PHASE 3 ODYSSEY TRIALS WITH/WITHOUT STATIN BACKGROUND

ATHEROSCLEROSIS (2016)

Journal

ATHEROSCLEROSIS

Volume 252, Issue -, Pages E231-E231

Publisher

ELSEVIER IRELAND LTD

DOI: 10.1016/j.atherosclerosis.2016.07.219

Keywords

-

Categories

Cardiac & Cardiovascular Systems Peripheral Vascular Disease

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study

Maciej Banach, Joanna Lewek, Kaja Pol, Daniel Rabczenko, Serban M. Balanescu, Vladimir Blaha, Richard Ceska, Piotr Jankowski, Stanislaw Surma, Genovefa Kolovou, Evangelos Liberopoulos, Florin Mitu, Magda Mitu, Franjo Husam Naji, Gyorgy Paragh, Magdalena Poplawska, Michal Vrablik, Daniel Pella

Summary: Despite better accessibility of effective lipid-lowering therapies, only a small percentage of high-risk cardiovascular patients achieve LDL-C goals. Patients from Central and Eastern Europe (CEE) have worse results due to limited access to appropriate therapy and suitable dosage intensity. This study compares physicians' therapeutic decisions on alirocumab dose selection in CEE countries versus other countries.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2023)

Add to Collection

Review Medicine, General & Internal

PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis

Safi U. Khan, Siva H. Yedlapati, Ahmad N. Lone, Qiukui Hao, Gordon Guyatt, Nicolas Delvaux, Geertruida E. (Trudy) Bekkering, Per Olav Vandvik, Irbaz Bin Riaz, Sheyu Li, Bert Aertgeerts, Nicolas Rodondi

Summary: This study aims to compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking maximally tolerated statin therapy or who are statin intolerant.

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Article Medicine, General & Internal

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE

Maciej Banach, Jose Luis Lopez-Sendon, Maurizio Averna, Bertrand Cariou, Megan Loy, Garen Manvelian, Isabela Batsu, Yann Poulouin, Daniel Gaudet

Summary: The study evaluated the real-life effectiveness of alirocumab treatment in high cardiovascular risk patients. The results showed that alirocumab treatment significantly reduced LDL-C levels in different statin intensity subgroups and prior ezetimibe therapy subgroups, with high patient adherence.

ARCHIVES OF MEDICAL SCIENCE (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

Chandni Bardolia, Nishita Shah Amin, Jacques Turgeon

Summary: This narrative review discusses the role of ezetimibe, PCSK9 inhibitors, BDA, and inclisiran in therapy, and describes their relative pharmacokinetic (PK) profiles, efficacy and safety as monotherapy and combination therapy, as well as the cardiovascular benefits when used for hypercholesterolemia.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk

Pere Rehues, Josefa Girona, Montse Guardiola, Nuria Plana, Roberto Scicali, Salvatore Piro, Ovidio Muniz-Grijalvo, Jose Luis Diaz-Diaz, Lluis Recasens, Marta Pinyol, Roser Rosales, Yaiza Esteban, Nuria Amigo, Lluis Masana, Daiana Ibarretxe, Josep Ribalta

Summary: This study evaluated the effects of iPCSK9 on glycoproteins A, B, and F, and found that iPCSK9 therapy not only reduced LDL cholesterol, but also decreased 1H-NMR glycoprotein signals, which correlated with a decrease in triglycerides and apoC-III.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagstrom, P. Gabriel Steg, Michael Szarek, Deepak L. Bhatt, Vera A. Bittner, Nicolas Danchin, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Evangelos Liberopoulos, Nikolaus Marx, Jennifer McGinniss, Garen Manvelian, Robert Pordy, Michel Scemama, Harvey D. White, Andreas M. Zeiher, Gregory G. Schwartz

Summary: This study investigated the predictive role of apolipoprotein B (apoB) levels in residual risk after acute coronary syndrome and found that apoB provides additional predictive information. The study also found that lowering apoB levels with the medication alirocumab can reduce cardiovascular events. Therefore, controlling apoB levels is important for reducing the risk after acute coronary syndrome.

CIRCULATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

Ulf Landmesser, Jennifer McGinniss, Ph Gabriel Steg, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Mirza Dilic, Shaun G. Goodman, J. Wouter Jukema, Megan Loy, Ivan Pecin, Robert Pordy, Steen H. Poulsen, Michael Szarek, Harvey D. White, Gregory G. Schwartz

Summary: In patients with recent ACS and high LDL-C despite optimized statin therapy, the addition of alirocumab allowed 94.6% to achieve the 2019 European guideline LDL-C goal <1.4 mmol/L, and 85.2% of those with recurrent cardiovascular events to achieve <1.0 mmol/L. In contrast, the addition of ezetimibe to optimized statin therapy was projected to achieve LDL-C <1.4 mmol/L in only 10.6% of patients at baseline.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review

Daniel J. Mcclintick, Robert P. Giugliano

Summary: PCSK9 inhibitors are a potent class of lipid-lowering therapies that are well tolerated and effective in a wide group of patients with high-risk atherosclerotic cardiovascular disease. Ongoing studies have the potential to broaden their indication, and alternative methods of PCSK9 inhibitors are being evaluated to provide easier and less expensive options for this important class of medication.

CURRENT OPINION IN LIPIDOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy

Naoto Kuyama, Yu Kataoka, Misa Takegami, Kunihiro Nishimura, Mariko Harada-Shiba, Mika Hori, Masatsune Ogura, Fumiyuki Otsuka, Yasuhide Asaumi, Teruo Noguchi, Kenichi Tsujita, Satoshi Yasuda

Summary: The study found that baseline mature PCSK9 level >228 ng/mL is associated with hyporesponse to statins, suggesting that mature PCSK9 might be a potential determinant of hyporesponse to statins.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

LDL lowering effect of PCSK9 inhibition is reduced in women

Veronika A. Myasoedova, Antoine Rimbert, Marina Camera, Cedric Le May, Romain Capoulade, Bertrand Cariou, Paolo Poggio

Summary: This study aimed to investigate the sex-differential effect of PCSK9 inhibition on LDL-C levels through pharmacological or genetic methods. The results showed that the reduction in LDL-C under PCSK9 inhibition was significantly greater in men than in women. The study emphasized the need for specific research to develop sex-specific recommendations for the management of ASCVD in women.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies

Tahir Mahmood, Jessica Minnier, Matthew K. Ito, Qian H. Li, Andrew Koren, Ivy W. Kam, Sergio Fazio, Michael D. Shapiro

Summary: This study aimed to investigate the prevalence of discordant plasma LDL-C/Lp(a) response to the PCSK9 inhibitor alirocumab, and a high prevalence of discordant response was observed, suggesting that alirocumab may reduce Lp(a) through alternative pathways.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development - (I) A Randomized Trial with PCSK9 Inhibitors

Morasa Sheikhy, Sarah J. Schrieber, Qin Sun, Victoria Gershuny, Murali K. Matta, Jane P. F. Bai, Xiulian Du, Giri Vegesna, Aanchal Shah, Kristin Prentice, Colleen Nalepinski, Issam Zineh, Yow-Ming Wang, David G. Strauss, Jeffry Florian

Summary: The FDA guidance on biosimilars development suggests that comparative clinical efficacy studies can be replaced by pharmacokinetic (PK) and pharmacodynamic (PD) similarity studies. However, there is a lack of PD comparability studies in biosimilar development, making it unclear how to plan these studies effectively.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Medical Laboratory Technology

Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition

Mingqi Ouyang, Chenyu Li, Die Hu, Daoquan Peng, Bilian Yu

Summary: The use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has shown efficacy in lowering the risk of atherosclerotic cardiovascular disease. However, a phenomenon of unusual responsiveness, with lower LDL-C reduction than average, has been observed. Several factors, including lack of adherence and abnormal effects of PCSK9 inhibitors, contribute to this unusual responsiveness. Understanding these mechanisms is crucial for effective management of LDL-C and cardiovascular risk.

CLINICA CHIMICA ACTA (2023)

Add to Collection

Article Immunology

Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis

Solenne Vigne, Donovan Duc, Benjamin Peter, Jessica Rebeaud, Yannick Yersin, Florian Ruiz, Valentine Bressoud, Tinh-Hai Collet, Caroline Pot

Summary: This study investigated the effect of circulating cholesterol levels on multiple sclerosis (MS) using a mouse model. The results showed that blood cholesterol level does not have a direct role in neuro-inflammatory diseases, and the protective effects of statins in MS are not related to circulating cholesterol.

JOURNAL OF NEUROINFLAMMATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort

Angelo B. Cefalu, Raffaella Garbelotto, Giuliana Mombelli, Matteo Pirro, Paolo Rubba, Marcello Arca, Claudio Borghi, Katia Bonomo, Stefano Gonnelli, Katia Massaroni, Giampaolo Tirone, Maurizio Averna

Summary: The ODYSSEY APPRISE trial evaluated the efficacy and safety of alirocumab in patients with hypercholesterolemia and high cardiovascular risk in a real-life setting. This report focuses on the Italian cohort in the trial. The results show that alirocumab effectively reduced LDL-C levels and was well tolerated in the Italian subgroup, confirming its benefits in reducing cardiovascular risk for patients.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program

Jorge Plutzky, Mark D. Benson, Kira Chaney, Tiffany Bui, Michael Kraft, Lina Matta, Marian McPartlin, David Zelle, Christopher P. Cannon, Anton Dodek, Thomas A. Gaziano, Akshay S. Desai, Calum A. MacRae, Benjamin M. Scirica

Summary: Utilizing EMR screening, a remote, algorithm-driven cholesterol management program successfully identified and improved LDL-C control in high ASCVD risk patients, providing a novel strategy for enhancing healthcare access and delivery.

AMERICAN HEART JOURNAL (2022)

Add to Collection

Article Endocrinology & Metabolism

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV

Samuel Dagogo-Jack, Christopher P. Cannon, David Z. Cherney, Francesco Cosentino, Jie Liu, Annpey Pong, Ira Gantz, Robert Frederich, James P. Mancuso, Richard E. Pratley

Summary: In the VERTIS CV trial, the effects of ertugliflozin on cardiorenal outcomes were consistent across subgroups of patients stratified by baseline glucose-lowering agent.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Clinical Neurology

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

Brian S. Wojeck, Silvio E. Inzucchi, Ian J. Neeland, James P. Mancuso, Robert Frederich, Urszula Masiukiewicz, Nilo B. Cater, Darren K. McGuire, Christopher P. Cannon, Henry Klar Yaggi

Summary: The study found that ertugliflozin significantly reduces the incidence of obstructive sleep apnea in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

SLEEP AND BREATHING (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Individualized therapy in statin intolerance: the key to success

Maciej Banach, Christopher P. Cannon, Francesco Paneni, Peter E. Penson

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

A polygenic risk score predicts atrial fibrillation in cardiovascular disease

Nicholas A. Marston, Amanda C. Garfinkel, Frederick K. Kamanu, Giorgio M. Melloni, Carolina Roselli, Petr Jarolim, David D. Berg, Deepak L. Bhatt, Marc P. Bonaca, Christopher P. Cannon, Robert P. Giugliano, Michelle L. O'Donoghue, Itamar Raz, Benjamin M. Scirica, Eugene Braunwald, David A. Morrow, Patrick T. Ellinor, Steven A. Lubitz, Marc S. Sabatine, Christian T. Ruff

Summary: In patients with cardiovascular conditions, AF PRS is a strong independent predictor of incident AF that provides complementary predictive value when added to a validated clinical risk score and NT-proBNP.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis

Eri Toda Kato, David A. Morrow, Jianping Guo, David D. Berg, Michael A. Blazing, Erin A. Bohula, Marc P. Bonaca, Christopher P. Cannon, James A. de Lemos, Robert P. Giugliano, Petr Jarolim, Tibor Kempf, L. Kristin Newby, Michelle L. O'Donoghue, Marc A. Pfeffer, Nader Rifai, Stephen D. Wiviott, Kai C. Wollert, Eugene Braunwald, Marc S. Sabatine

Summary: Levels of growth differentiation factor 15 (GDF-15) have been associated with various cardiovascular events. This study analyzed data from eight trials and found that higher GDF-15 concentration was independently associated with increased rates of cardiovascular death/hospitalization for heart failure and major adverse cardiovascular events. However, the prognostic association of GDF-15 with future myocardial infarction and stroke remained significant only in patients stabilized after recent acute coronary syndrome or with stable atherosclerotic cardiovascular disease, not in acute coronary syndrome patients.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Endocrinology & Metabolism

Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin

Karen D. Corbin, Samuel Dagogo-Jack, Christopher P. Cannon, David Z. I. Cherney, Francesco Cosentino, Robert Frederich, Jie Liu, Annpey Pong, Jianxin Lin, Nilo B. Cater, Richard E. Pratley

Summary: The aim of this study was to explore the relationship between indices of hepatic steatosis/fibrosis and cardiorenal outcomes. The results showed that higher fibrosis-4 score was associated with cardiovascular events, while higher hepatic steatosis index was associated with heart failure. Liver enzymes and hepatic steatosis index decreased over time with ertugliflozin.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Letter Endocrinology & Metabolism

Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease

Joseph M. Kim, Deepak L. Bhatt, Samuel Dagogo-Jack, David Z. I. Cherney, Francesco Cosentino, Darren K. McGuire, Richard E. Pratley, Chih-Chin Liu, Nilo B. Cater, Robert Frederich, James P. Mancuso, Christopher P. Cannon

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Endocrinology & Metabolism

Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV

Samuel Dagogo-Jack, Robert Frederich, Jie Liu, Christopher P. Cannon, Harry Shi, David Z. Cherney, Francesco Cosentino, Urszula Masiukiewicz, Ira Gantz, Richard E. Pratley

Summary: In the VERTIS CV trial, ertugliflozin treatment decreased the likelihood of insulin initiation, delayed the time to insulin initiation by up to approximately 1.8 years, and reduced insulin dose requirements without increasing the incidence of hypoglycemia events.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

Add to Collection

Article Multidisciplinary Sciences

Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study

Helena A. K. Lapatto, Minna Kuusela, Aino Heikkinen, Maheswary Muniandy, Birgitta W. van der Kolk, Swetha Gopalakrishnan, Noora Pollanen, Martin Sandvik, Mark S. Schmidt, Sini Heinonen, Sina Saari, Juho Kuula, Antti Hakkarainen, Janne Tampio, Tuure Saarinen, Marja-Riitta Taskinen, Nina Lundbom, Per-Henrik Groop, Marja Tiirola, Pekka Katajisto, Marko Lehtonen, Charles Brenner, Jaakko Kaprio, Satu Pekkala, Miina Ollikainen, Kirsi H. Pietilainen, Eija Pirinen

Summary: Nicotinamide riboside (NR), a precursor of nicotinamide adenine dinucleotide (NAD(+)), has shown promise in improving obesity-associated mitochondrial dysfunction and metabolic syndrome. However, short-term clinical trials have not yielded positive results. This study aimed to investigate the long-term effects of NR supplementation on mitochondrial biogenesis and metabolic health in humans. The results showed that NR improved NAD(+) metabolism, muscle mitochondrial number, myoblast differentiation, gut microbiota composition, and epigenetic control of gene expression. However, it did not improve adiposity or metabolic health.

SCIENCE ADVANCES (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network

Alexander J. Blood, Christopher P. Cannon, William J. Gordon, Charlotte Mailly, Taylor MacLean, Samantha Subramaniam, Michela Tucci, Jennifer Crossen, Hunter Nichols, Kavishwar B. Wagholikar, David Zelle, Marian McPartlin, Lina S. Matta, Michael Oates, Samuel Aronson, Shawn Murphy, Adam Landman, Naomi D. L. Fisher, Thomas A. Gaziano, Jorge Plutzky, Benjamin M. Scirica

Summary: This study implemented and evaluated a remote hypertension and cholesterol management program in a diverse healthcare network. The program resulted in improved blood pressure and cholesterol control among patients, regardless of their race, ethnicity, or primary language.

JAMA CARDIOLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study

Suzanne V. Arnold, James A. de Lemos, Luke Zheng, Robert S. Rosenson, Christie M. Ballantyne, Shushama Alam, Deepak L. Bhatt, Christopher P. Cannon, Mikhail Kosiborod, GOULD Investigators

Summary: The study aimed to examine the improvement in the use of optimal medical therapy (OMT) for patients with atherosclerotic cardiovascular disease (ASCVD) and diabetes. The study found that the use of secondary prevention in US patients with ASCVD and diabetes was suboptimal, with minimal improvement over time.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Endocrinology & Metabolism

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy

Marja-Riitta Taskinen, Niina Matikainen, Elias Bjornson, Sanni Soderlund, Jussi Inkeri, Antti Hakkarainen, Helka Parviainen, Carina Sihlbom, Annika Thorsell, Linda Andersson, Martin Adiels, Chris J. Packard, Jan Boren

Summary: This study investigated the hypothesis that individuals with type 2 diabetes on statin therapy may have significant abnormalities in the metabolism of intestinally derived lipoproteins. The findings suggest that in these individuals, there are increased production and longer circulation time of ApoB-48-containing lipoproteins, which may contribute to residual cardiovascular disease risk.

DIABETOLOGIA (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study

Elias Bjornson, Martin Adiels, Marja-Riitta Taskinen, Stephen Burgess, Aidin Rawshani, Jan Boren, Chris J. Packard

Summary: In this study, the association between triglyceride-rich lipoproteins (TRL) and coronary heart disease (CHD) was investigated using population data from the UK Biobank. The results suggest that TRL/remnant cholesterol has a stronger and independent association with CHD compared to LDL cholesterol. Moreover, different genetic clusters impact TRL/remnants and LDL differentially, with TRL/remnants exhibiting a higher atherogenicity per particle than LDL.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Meeting Abstract Cardiac & Cardiovascular Systems

EFFICACY OF ERTUGLIFLOZIN ON HEART FAILURE HOSPITALIZATION AND HF DEATH ACROSS THE WATCH-DM RISK SCORE: A SECONDARY ANALYSIS OF THE VERTIS CV TRIAL

Matthew Segar, Darren K. McGuire, Robert Frederich, David Z. I. Cherney, Christopher P. Cannon, Francesco Cosentino, Samuel Dagogo-Jack, Richard Pratley, Nilo B. Cater, Mario Maldonado, Birol Emir, Darren Jeng, Harry Shi, Ambarish Pandey

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.